As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc. reportedly is being eyed by pharma giant Pfizer Inc. for a possible collaboration or even outright acquisition. (BioWorld Today)
No Abstract Assistant Managing EditorWith buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.
With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today)
PDL BioPharma Inc., which promised significant returns to shareholders since adopting an unusual royalty-collecting business model following last year's spinoff of its R&D division, has opted to monetize a percentage of its antibody royalties from Genentech Inc. products to return a special cash dividend by year-end. (BioWorld Today)
